Product nameDyLight® 488 Conjugation Kit (Fast) - Lightning-Link®
DyLight® 488 Conjugation Kit / DyLight® 488 Labeling Kit (ab201799) uses a simple and quick process for DyLight® 488 labeling / conjugation of antibodies. It can also be used to conjugate other proteins or peptides. Learn about our antibody labeling kits and their advantages.
To conjugate an antibody to DyLight® 488 using this kit:
- add modifier to antibody and incubate for 15 mins
- add quencher and incubate for 5 mins
The DyLight® 488 conjugated antibody can be used immediately in WB, ELISA, IHC etc. No further purification is required and 100% of the antibody is recovered for use.
Learn about buffer compatibility below; for incompatible buffers and low antibody concentrations, use our rapid antibody purification and concentration kits. Use the FAQ to learn more about the technology, or about conjugating other proteins and peptides to DyLight® 488.
Custom size conjugation kits up to 100 mg are available on demand. Please contact us to discuss your requirements.
This product is manufactured by Expedeon, an Abcam company, and was previously called Lightning-Link® Rapid DyLight® 488 Labeling Kit. 322-0015 is the same as the 1 mg size. 322-0030 is the same as the 3 x 10 ug size. 322-0010 is the same as the 3 x 100 ug size. 322-0005 is the same as the 100 ug size.
Amount and volume of antibody for conjugation to Dylight ® 488
Kit size Recommended
amount of antibody1
amount of antibody
3 x 10 µg 3 x 10 µg 3 x 20 µg 3 x 10 µL 100 µg 1 x 100 µg 1 x 200 µg 1 x 100 µL 3 x 100 µg 3 x 100 µg 3 x 200 µg 3 x 100 µL 1 mg 1 x 1 mg 1 x 2 mg 1 x 1 mL
1 Using the maximum amount of antibody may result in less labelling per antibody.
2 Ideal antibody concentration is 1mg/ml. 0.5 - 1 mg/ml can be used if the maximum antibody volume is not exceeded. Antibodies > 2mg/ml or < 0.5 mg/ml should be diluted /concentrated.
Buffer Requirements for Conjugation
Buffer should be pH 6.5-8.5.
Compatible buffer constituents
If a concentration is shown, then the constituent should be no more than the concentration shown. If several constituents are close to the limit of acceptable concentration, then this can inhibit conjugation.
50mM / 0.6% Tris1 0.1% BSA2 50% glycerol 0.1% sodium azide PBS Potassium phosphate Sodium chloride HEPES Sucrose Sodium citrate EDTA Trehalose
1 Tris buffered saline is almost always ≤ 50 mM / 0.6%
2 BSA can also interfere with the use of the conjugated antibody in tissue staining.
Incompatible buffer constituents
Thiomerosal Proclin Glycine Arginine Glutathione DTT
Only purified antibodies are suitable for use, ie. where other proteins, peptides, or amino acids are not present: antibodies in ascites fluid, serum or hybridoma culture media are incompatible.
DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Storage instructionsStore at -20°C. Please refer to protocols.
Components 1 mg 100 µg 3 x 10 µg 3 x 100 µg ab274013 - Dylight® 488 Conjugation Mix 1 x 1mg 1 x 100µg 3 x 10µg 3 x 100µg ab273994 - Modifier reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl ab273995 - Quencher reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl
Monaco, Sara, et al used DyLight 488 Conjugation Kit (Fast) - Lightning-Link® (ab201799) as part of examining the co-localization of Smoothened and AC3 in primary cilia. They used the kit to conjugate DyLight® 488 to anti-AC3 antibody for use in flow cytometry.
(A) Representative dot plots of untreated (Control) and SAG-treated samples (SAG) from E18 embryos immunostained for AC3-FITC and Smoothened-APC (Smo-APC). (B) Quantification of the percentage of Smo+AC3+ particles. Bar graphs show mean ± SEM, p-values are calculated with Student's t-test. Statistically significant differences are indicated with asterisks (*p < 0.05, **p < 0.01).
Dorfmueller, Simone, et al used DyLight® 488 Conjugation Kit (Fast) - Lightning-Link® (ab201799) as part of characterizing antibody-labelled human corneal endothelial cells (hCECs) and stromal fibroblasts. They used the kit to conjugate DyLight® 488 to C1M2-2-B8 scFv or IgG-B8 full-size antibody for use in flow cytometry.
Primary hCECs or stromal fibroblasts were incubated with C1M2-2-B8 scFv or IgG-B8 full-size antibody conjugated to DyLight® 488 (4 µg/ml). (a) The histogram for unlabelled hCECs (black) is overlaid with those for scFv and IgG-B8 labelled cells as indicated. Similarly, the histogram for unlabelled stromal fibroblasts (orange) is overlaid with those for scFv and IgG-B8 labelled fibroblasts. (b) The histograms for C1M2-2-B8 scFv labelled hCECs and stromal fibroblasts were shown on the same graph, as for the histograms for IgG-B8 labelled hCECs and stromal fibroblasts. The peak separation between fibroblasts and hCECs were similar in magnitude with either scFv or IgG labelling.
Lalo, Ulyana, et al used DyLight® 488 Conjugation Kit (Fast) - Lightning-Link® (ab201799) as part of examining the colocalization of vesicular ATP transporters with exocytotic organelle markers. They used the kit to conjugate DyLight® 488 to various antibodies for use in multiphoton fluorescent microscopy.
Living, acutely isolated cortical astrocytes were labeled with antibodies to vesicular transporters (VNUT1 and VGLUT1) and synaptic vesicle (SV2A) and lysosomal (LAMP3 and Cathepsin-D) markers. Antibodies were conjugated to fluorescent dyes DyLight488 (green) and DyLight594 (red) prior to astrocyte labeling. (A-D) The representative two-photon fluorescence images (maximal intensity projections of Z-stack) and results of colocalization analysis, carried out using NIH ImageJ 1.43 software. The correlation between green and red fluorescence (images in the right column) is depicted as a product of the relative differences from the mean (PDM) for each pixel; the pseudocolor PDM images were generated as an output of ImageJ analysis routine. Positive values (bright yellow) are indicative for good co-localization of green and red signals, negative values (blue-violet) indicate segregation, and black color shows the lack of correlation. Note the different extent of scale for PDM values in (A-D). All scale bars in (A-D) are 5 µm.
Mellema M et al. used ab201799 as part of examining mineralo-organic nanoparticles in feline urine.
They used the kit to conjugate DyLight® 488 to alendronate compound and osteopontin protein for use in Nanoparticle Tracking Analysis (NTA®).
A: Representative histogram showing size distribution and cumulative percentage (left) of submicron particulate matter in healthy feline urine after labeling with DyLight 488 conjugated alendronate. A representative frame from the captured video analyzed by NTA is shown as well (right). Note the strongly preferential binding to primary CNP that lack an outer layer of protein or mucus.
B: Representative histogram showing averaged sizing and relative abundance data (left; SE in red) and individual analyses from the assessment (right) of this representative sample of healthy feline urine after labeling with DyLight 488 conjugated osteopontin. Note the strongly preferential binding to primary naturally-occurring CNP that lack an outer layer of protein or mucus.
ab201799 has been referenced in 7 publications.
- Alshafie W et al. Regulated resurfacing of a somatostatin receptor storage compartment fine-tunes pituitary secretion. J Cell Biol 219:N/A (2020). PubMed: 31825461
- Osborne N et al. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases. Am J Physiol Gastrointest Liver Physiol 317:G682-G693 (2019). PubMed: 31433212
- Chang WL et al. TBC1D20 deficiency induces Sertoli cell apoptosis by triggering irreversible endoplasmic reticulum stress in mice. Mol Hum Reprod 25:773-786 (2019). PubMed: 31633178
- Smith JP et al. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207 (2018). ICC/IF . PubMed: 29043413
- Monaco S et al. A Flow Cytometry-Based Approach for the Isolation and Characterization of Neural Stem Cell Primary Cilia. Front Cell Neurosci 12:519 (2018). PubMed: 30692915
- Bosse KR et al. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:295-309.e12 (2017). PubMed: 28898695
- Jia CE et al. Pendrin, an anion exchanger on lung epithelial cells, could be a novel target for lipopolysaccharide-induced acute lung injury mice. Am J Transl Res 8:981-92 (2016). PubMed: 27158384